Arcutis Q1 product revenue $63.8M (+196% YoY); net loss narrows; appoints new CFO

Arcutis Biotherapeutics, Inc.

2025-Q1 EPS reported -$0.20 revenue$65,846,000

Net product revenue $63.8M, up 196% YoY; down 2% QoQ due to deductible resets.
Net loss $25.1M ($0.20/shr) vs $35.4M ($0.32/shr) YoY improvement.
Latha Vairavan appointed CFO effective May 6, 2025.
Patent litigation against Padagis stayed; all deadlines cancelled; 30-month extension.
PDUFA May 22 for ZORYVE foam 0.3% for scalp/body psoriasis; sNDA for cream 0.05% with PDUFA Oct 13.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.